Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis

S Bringhen, M Offidani, S Palmieri, F Pisani, R Rizzi, S Spada, A Evangelista, N Di Renzo, P Musto, M Marcatti, R Vallone, S Storti, A Bernardini, R Centurioni, E Aitini, A Palmas, O Annibali, E Angelucci, P Ferrando, A BaraldiS Rocco, A Andriani, A Siniscalchi, V De Stefano, V Meneghini, A Palumbo, S Grammatico, M Boccadoro, A Larocca

Research output: Contribution to journalArticle

Abstract

Introduction: Early toxic death (≤60 days of diagnosis) in elderly multiple myeloma (MM) patients is attributable to active disease, age and co-morbidities. Rate of early toxic deaths is 10% with conventional chemotherapy mainly due to infection and renal failure. Novel agents have improved MM outcome at the expense of newer toxicity. Methods: We analyzed 1146 individual patient data to assess toxic deaths during induction treatment with first-generation novel agents thalidomide, lenalidomide, bortezomib. Results: During first-line therapy, 119/1146 patients (10%) died for any cause, and 47/1146 (4%) due to toxicity, including 12/1146 (1%) early deaths. The 24-month cumulative incidence was 4.1% without any difference between bortezomib (18/503 patients, 4%) and lenalidomide (29/643patients, 5%; p = 0.31). Toxic deaths occurred in 34/1039 (3%) patients
Original languageEnglish
Pages (from-to)27-35
Number of pages9
JournalCritical Reviews in Oncology/Hematology
Volume130
DOIs
Publication statusPublished - 2018

Fingerprint

Thalidomide
Poisons
Mortality
Multiple Myeloma
Renal Insufficiency
Bortezomib
lenalidomide
Morbidity
Drug Therapy
Incidence
Therapeutics
Infection

Cite this

Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis. / Bringhen, S; Offidani, M; Palmieri, S; Pisani, F; Rizzi, R; Spada, S; Evangelista, A; Di Renzo, N; Musto, P; Marcatti, M; Vallone, R; Storti, S; Bernardini, A; Centurioni, R; Aitini, E; Palmas, A; Annibali, O; Angelucci, E; Ferrando, P; Baraldi, A; Rocco, S; Andriani, A; Siniscalchi, A; De Stefano, V; Meneghini, V; Palumbo, A; Grammatico, S; Boccadoro, M; Larocca, A.

In: Critical Reviews in Oncology/Hematology, Vol. 130, 2018, p. 27-35.

Research output: Contribution to journalArticle

Bringhen, S, Offidani, M, Palmieri, S, Pisani, F, Rizzi, R, Spada, S, Evangelista, A, Di Renzo, N, Musto, P, Marcatti, M, Vallone, R, Storti, S, Bernardini, A, Centurioni, R, Aitini, E, Palmas, A, Annibali, O, Angelucci, E, Ferrando, P, Baraldi, A, Rocco, S, Andriani, A, Siniscalchi, A, De Stefano, V, Meneghini, V, Palumbo, A, Grammatico, S, Boccadoro, M & Larocca, A 2018, 'Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis', Critical Reviews in Oncology/Hematology, vol. 130, pp. 27-35. https://doi.org/10.1016/j.critrevonc.2018.07.003
Bringhen, S ; Offidani, M ; Palmieri, S ; Pisani, F ; Rizzi, R ; Spada, S ; Evangelista, A ; Di Renzo, N ; Musto, P ; Marcatti, M ; Vallone, R ; Storti, S ; Bernardini, A ; Centurioni, R ; Aitini, E ; Palmas, A ; Annibali, O ; Angelucci, E ; Ferrando, P ; Baraldi, A ; Rocco, S ; Andriani, A ; Siniscalchi, A ; De Stefano, V ; Meneghini, V ; Palumbo, A ; Grammatico, S ; Boccadoro, M ; Larocca, A. / Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis. In: Critical Reviews in Oncology/Hematology. 2018 ; Vol. 130. pp. 27-35.
@article{b8be14a9855343bdb3cfb38b7fe91163,
title = "Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis",
abstract = "Introduction: Early toxic death (≤60 days of diagnosis) in elderly multiple myeloma (MM) patients is attributable to active disease, age and co-morbidities. Rate of early toxic deaths is 10{\%} with conventional chemotherapy mainly due to infection and renal failure. Novel agents have improved MM outcome at the expense of newer toxicity. Methods: We analyzed 1146 individual patient data to assess toxic deaths during induction treatment with first-generation novel agents thalidomide, lenalidomide, bortezomib. Results: During first-line therapy, 119/1146 patients (10{\%}) died for any cause, and 47/1146 (4{\%}) due to toxicity, including 12/1146 (1{\%}) early deaths. The 24-month cumulative incidence was 4.1{\%} without any difference between bortezomib (18/503 patients, 4{\%}) and lenalidomide (29/643patients, 5{\%}; p = 0.31). Toxic deaths occurred in 34/1039 (3{\%}) patients",
author = "S Bringhen and M Offidani and S Palmieri and F Pisani and R Rizzi and S Spada and A Evangelista and {Di Renzo}, N and P Musto and M Marcatti and R Vallone and S Storti and A Bernardini and R Centurioni and E Aitini and A Palmas and O Annibali and E Angelucci and P Ferrando and A Baraldi and S Rocco and A Andriani and A Siniscalchi and {De Stefano}, V and V Meneghini and A Palumbo and S Grammatico and M Boccadoro and A Larocca",
year = "2018",
doi = "10.1016/j.critrevonc.2018.07.003",
language = "English",
volume = "130",
pages = "27--35",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis

AU - Bringhen, S

AU - Offidani, M

AU - Palmieri, S

AU - Pisani, F

AU - Rizzi, R

AU - Spada, S

AU - Evangelista, A

AU - Di Renzo, N

AU - Musto, P

AU - Marcatti, M

AU - Vallone, R

AU - Storti, S

AU - Bernardini, A

AU - Centurioni, R

AU - Aitini, E

AU - Palmas, A

AU - Annibali, O

AU - Angelucci, E

AU - Ferrando, P

AU - Baraldi, A

AU - Rocco, S

AU - Andriani, A

AU - Siniscalchi, A

AU - De Stefano, V

AU - Meneghini, V

AU - Palumbo, A

AU - Grammatico, S

AU - Boccadoro, M

AU - Larocca, A

PY - 2018

Y1 - 2018

N2 - Introduction: Early toxic death (≤60 days of diagnosis) in elderly multiple myeloma (MM) patients is attributable to active disease, age and co-morbidities. Rate of early toxic deaths is 10% with conventional chemotherapy mainly due to infection and renal failure. Novel agents have improved MM outcome at the expense of newer toxicity. Methods: We analyzed 1146 individual patient data to assess toxic deaths during induction treatment with first-generation novel agents thalidomide, lenalidomide, bortezomib. Results: During first-line therapy, 119/1146 patients (10%) died for any cause, and 47/1146 (4%) due to toxicity, including 12/1146 (1%) early deaths. The 24-month cumulative incidence was 4.1% without any difference between bortezomib (18/503 patients, 4%) and lenalidomide (29/643patients, 5%; p = 0.31). Toxic deaths occurred in 34/1039 (3%) patients

AB - Introduction: Early toxic death (≤60 days of diagnosis) in elderly multiple myeloma (MM) patients is attributable to active disease, age and co-morbidities. Rate of early toxic deaths is 10% with conventional chemotherapy mainly due to infection and renal failure. Novel agents have improved MM outcome at the expense of newer toxicity. Methods: We analyzed 1146 individual patient data to assess toxic deaths during induction treatment with first-generation novel agents thalidomide, lenalidomide, bortezomib. Results: During first-line therapy, 119/1146 patients (10%) died for any cause, and 47/1146 (4%) due to toxicity, including 12/1146 (1%) early deaths. The 24-month cumulative incidence was 4.1% without any difference between bortezomib (18/503 patients, 4%) and lenalidomide (29/643patients, 5%; p = 0.31). Toxic deaths occurred in 34/1039 (3%) patients

U2 - 10.1016/j.critrevonc.2018.07.003

DO - 10.1016/j.critrevonc.2018.07.003

M3 - Article

VL - 130

SP - 27

EP - 35

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

ER -